Comparative Pharmacology
Head-to-head clinical analysis: MILONTIN versus SUBVENITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MILONTIN versus SUBVENITE.
MILONTIN vs SUBVENITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases seizure threshold by inhibiting voltage-gated sodium channels and enhancing GABAergic inhibition.
SUBVENITE (rasagiline) is a selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It inhibits the breakdown of dopamine by blocking MAO-B, increasing dopamine levels in the striatum.
Oral, 500 mg twice daily; may increase by 250-500 mg/day every 2-3 days; usual dose 1-2 g/day in 2-3 divided doses; maximum 3 g/day.
Sublingual tablet: 2-4 mg sublingually every 8-12 hours as needed for breakthrough pain; maximum 4 doses per day.
None Documented
None Documented
Terminal elimination half-life is 6–8 hours in adults, longer in children (8–12 hours) and elderly (10–14 hours); clinical context: requires multiple daily dosing to maintain therapeutic levels.
Terminal elimination half-life is approximately 70-90 hours in adults with normal renal function, allowing once-daily dosing.
Primarily hepatic metabolism and renal excretion; approximately 60% of a dose is excreted in urine as conjugated metabolite (phensuximide glucuronide), with 15% as unchanged drug; 20% eliminated in feces.
Renal elimination of unchanged drug accounts for approximately 45-50% of the administered dose; fecal elimination via biliary excretion accounts for approximately 40-45%.
Category C
Category C
Antiepileptic
Antiepileptic